Negative regulation of cytokine signaling pathways

Annual Review of Immunology

Volumn 18, Issue , 2000, Pages 143-164

  Yasukawa, Hideo ^a   Sasaki, Atsuo ^a   Yoshimura, Akihiko ^a  

^a KURUME UNIVERSITY   (Japan)

Author keywords

CIS; Interferon gamma; JAB; JAK; Negative regulation; SH2 domain; SOCS; SSI; STAT; Tyrosine kinase

Indexed keywords

CYTOKINE RECEPTOR; PROTEIN KINASE C INHIBITOR; STAT PROTEIN;

CELL DIFFERENTIATION; CELL GROWTH; ENZYME ACTIVITY; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARRIER PROTEINS; CYTOKINES; DNA-BINDING PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-TYROSINE KINASES; PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 0034082217     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.18.1.143     Document Type: Review

References (101)

1. Darnell JE Jr. 1997. STATs and gene regulation. Science 277:1630-35
2. Hoey T, Schindler U. 1998. STAT structure and function in signaling. Curr. Opin. Genet. Dev. 8:582-87
3. Liu KD, Gaffen SL, Goldsmith MA. 1998. JAK/STAT signaling by cytokine receptors. Curr. Opin. Immunol. 10:271-78
4. Leonard WJ, O'Shea JJ. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16:293-322
5. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. 1997. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. USA 94:7239-44
6. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. 1997. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11:179-86
7. Nakajima H, Liu XW, Wynshaw-Boris A, Rosenthal LA, Imada K, Finbloom DS, Hennighausen L, Leonard WJ. 1997. An indirect effect of Stat5a in IL-2-induced proliferation: a critical role for Stat5a in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 7:691-701
8. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93:841-50
9. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC, Ihle JN. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10:249-59
10. Rook GA, Hernandez-Pando R, Lightman SL. 1994. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance. Immunol. Today 15:301-3
11. Sengupta TK, Schmitt EM, Ivashkiv LB. 1996. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc. Natl. Acad. Sci. USA 93:9499-9504
12. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18:2553-58
13. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol 18: 2545-52
14. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278:1309-12
15. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van RL, Baens M, Van BH, Marynen P. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t (9;12) in a lymphoid and t (9;15;12) in a myeloid leukemia. Blood 90:2535-40
16. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. 1997. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 90:2057-61
17. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. 1995. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729-38
18. Kim TK, Maniatis T. 1996. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273:1717-19
19. Strous GJ, van Kerkhof P, Govers R, Ciechanover A, Schwartz AL. 1996. The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J. 15:3806-12
20. Wang D, Stravopodis D, Teglund S, Kitazawa J, Ihle JN. 1996. Naturally occurring dominant negative variants of Stat5. Mol. Cell. Biol. 16:6141-48
21. Azam M, Lee C, Strehlow I, Schindler C. 1997. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity 6:691-701
22. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803-5
23. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K. 1998. Inhibition of Stall-mediated gene activation by PIAS1. Proc. Natl. Acad. Sci. USA 95:10626-31
24. Gauzzi MC, Velazquez L, McKendry R, Mogensen KE, Fellous M, Pellegrini S. 1996. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase. J. Biol. Chem. 271: 20494-500
25. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN. 1997. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17: 2497-2501
26. Zhou YJ, Hanson EP, Chen YQ, Magnuson K, Chen M, Swann PG, Wange RL, Changelian PS, O'Shea JJ. 1997. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94:13850-55
27. Liu KD, Gaffen SL, Goldsmith MA, Greene WC. 1997. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. Curr. Biol. 7:817-26
28. Weiss A, Schlessinger J. 1998. Switching signals on or off by receptor dimerization. Cell 94:277-80
29. Haque SJ, Harbor P, Tabrizi M, Yi T, Williams BR. 1998. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4-and IL-13-dependent signal transduction. J. Biol. Chem. 273:33893-96
30. Migone TS, Cacalano NA, Taylor N, Yi T, Waldmann TA, Johnston JA. 1998. Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. Proc. Natl. Acad. Sci. USA 95:3845-50
31. David M, Chen HE, Goelz S, Lamer AC, Neel BG. 1995. Differential regulation of the alpha/beta interferon-stimulated Jak/ Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15:7050-58
32. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. 1996. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol. Cell. Biol. 16:6985-92
33. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, Thomas ML, Beier DR. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73:1445-54
34. Tabrizi M, Yang W, Jiao H, DeVries EM, Platanias LC, Arico M, Yi T. 1998. Reduced Tyk2/SHP-1 interaction and lack of SHP-1 mutation in a kindred of familial hemophagocytic lymphohistiocytosis. Leukemia 12:200-6
35. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch KA. 1998. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol. Cell. Biol. 18:2089-99
36. Plas DR, Johnson R, Pingel JT, Matthews RJ, Dalton M, Roy G, Chan AC, Thomas ML. 1996. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science 272:1173-76
37. Kim H, Hawley TS, Hawley RG, Baumann H. 1998. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells. Mol. Cell. Biol. 18:1525-33
38. You M, Yu DH, Feng GS. 1999. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. Cell. Biol. 19:2416-24
39. Huber M, Helgason CD, Damen JE, Liu L, Humphries RK, Krystal G. 1998. The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc. Natl. Acad. Sci. USA 95:11330-35
40. Liu Q, Oliveira-Dos-Santos AJ, Mariathasan S, Bouchard D, Jones J, Sarao R, Kozieradzki I, Ohashi PS, Penninger JM, Dumont DJ. 1998. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J. Exp. Med. 188:1333-42
41. Helgason CD, Damen JE, Rosten P, Grewal R, Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G, Humphries RK. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1610-20
42. Liu Q, Sasaki T, Kozieradzki I, Wakeham A, Itie A, Dumont DJ, Penninger JM. 1999. SHIP is a negative regulator of growth factor receptor-mediated PKB/ Akt activation and myeloid cell survival. Genes Dev. 13:786-91
43. Barber DL, Mason JM, Fukazawa T, Reedquist KA, Druker BJ, Band H, D'Andrea AD. 1997. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins. Blood 89:3166-74
44. Odai H, Sasaki K, Iwamatsu A, Hanazono Y, Tanaka T, Mitani K, Yazaki Y, Hirai H. 1995. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J. Biol. Chem. 270: 10800-5
45. Jongeward GD, Clandinin TR, Sternberg PW. 1995. sli-1, a negative regulator of let-23-mediated signaling in C. elegans. Genetics 139:1553-66
46. Yoon CH, Lee J, Jongeward GD, Sternberg PW. 1995. Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl. Science 269:1102-5
47. Ota Y, Samelson LE. 1997. The product of the proto-oncogene c-cbl: a negative regulator of the Syk tyrosine kinase. Science 276:418-20
48. Rellahant BL, Graham LJ, Stoica B, DeBell KE, Bonvini E. 1997. Cbl-mediated regulation of T cell receptor-induced API activation. Implications for activation via the Ras signaling pathway. J. Biol. Chem. 272:30806-11
49. Keane MM, Rivero-lezcano OM, Mitcell JA, Robbins KC, Lipkowitz S. 1995. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10:2367-77
50. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CB, Langdon WY, Bowtell DD. 1998. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol. 18:4872-82
51. Bowtell DDL, Langdon WY. 1995. The protein product of the c-cbl oncogene rapidly complexes with the EGF receptor and is tyrosine phosphorylated following EGF stimulation. Oncogene 11:1561-67
52. Miyake S, Lupher ML Jr, Druker B, Band H. 1998. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc. Natl. Acad. Sci. USA 95:7927-32
53. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. 1998. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12:3663-74
54. Ueno H, Sasaki K, Miyagawa K, Honda H, Mitani K, Yazaki Y, Hirai H. 1997. Antisense repression of proto-oncogene c-Cbl enhances activation of the JAK-STAT pathway but not the ras pathway in epidermal growth factor receptor signaling. J. Biol. Chem. 272:8739-43
55. Yokouchi M, Suzuki R, Masuhara M, Komiya S, Inoue A, Yoshimura A. 1997. Cloning and characterization of APS, an adaptor molecule containing PH and SH2 domains that is tyrosine phosphorylated upon B-cell receptor stimulation. Oncogene 15:7-15
56. Rui L, Mathews LS, Hotta K, Gustafson TA, Carter-Su C. 1997. Identification of SH2-Bbeta as a substrate of the tyrosine kinase JAK2 involved in growth hormone signaling. Mol. Cell. Biol. 17: 6633-44
57. Wakioka T, Sasaki A, Mitsui K, Yokouchi M, Inoue A, Komiya S, Yoshimura A. 1999. APS, an adaptor protein containing PH and SH2 domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia 13:760-67
58. Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T, Miyajima A. 1995. A novel cytokine-inducible gene CIS encodes an SH2 containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:2816-26
59. Uchida K, Yoshimura A, Inazawa J, Yanagisawa K, Osada H, Masuda A, Saito T, Takahashi T, Miyajima A, Takahashi T. 1997. Molecular cloning of CISH, chromosome assignment to 3p21.3, and analysis of expression in fetal and adult tissues. Cytogenet. Cell. Genet. 78:209-12
60. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A. 1997. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89:3148-54
61. Verdier F, Chretien S, Muller O, Varlet P, Yoshimura A, Gisselbrecht S, Lacombe C, Mayeux P. 1998. Proteasomes regulate erythropoietin receptor and signal ransducer and activator of transcription 5(STAT5) activation. Possible involvement of the ubiquitinated CIS protein. J. Biol. Chem. 273:28185-90
62. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Kent SB, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, Baca M. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96:2071-76
63. Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC, Conaway JW. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872-81
64. Tyers M, Willems AR. 1999. One ring to rule a superfamily of E3 ubiquitin ligases. Science 284:601,603-4
65. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, Tsuji K, Nakahata T, Okabe M, Yamada S, Yoshimura A. 1999. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2 protein-1 (CIS1) transgenic mice Mol. Cell. Biol. 19:6396-6407
66. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917-21
67. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921-24
68. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924-29
69. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A. 1997. Cloning and characterization of novel CIS family genes. Biochem. Biophys. Res. Commun. 239:439-46
70. Ohya Ki, Kajigaya S, Yamashita Y, Miyazato A, Hatake K, Miura Y, Ikeda U, Shimada K, Ozawa K, Mano H. 1997. SOCS-1/JAB/SSI-1 can bind to and suppress Tec protein-tyrosine kinase. J. Biol. Chem. 272:27178-82
71. De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R. 1999. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J. 18:904-5
72. Losman JA, Chen XP, Hilton D, Rothman P. 1999. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. J. Immunol. 162:3770-74
73. Venkataraman C, Leung S, Salvekar A, Mano H, Schindler U. 1999. Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation. J. Immunol. 162:4053-61
74. Suzuki R, Sakamoto H, Yasukawa H, Masuhara M, Wakioka T, Sasaki A, Yuge K, Komiya S, Inoue A, Yoshimura A. 1998. CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells. Oncogene 17:2271-78
75. Sakamoto H, Yasukawa H, Masuhara M, Tanimura S, Sasaki A, Yuge K, Ohtsubo M, Ohtsuka A, Fujita T, Ohta T, Furukawa Y, Iwase S, Yamada H, Yoshimura A. 1998. A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. Blood 92:1668-76
76. Naka T, Matsumoto T, Narazaki M, Fujimoto M, Monta Y, Ohsawa Y, Saito H, Nagasawa T, Uchiyama Y, Kishimoto T. 1998. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sci. USA 95:15577-82
77. Starr R, Metcalf D, Elefanty AG, Brysha M, Willson TA, Nicola NA, Hilton DJ, Alexander WS. 1998. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc. Natl. Acad. Sci. USA 95:14395-99
78. Metcalf D, Alexander WS, Elefanty AG, Nicola NA, Hilton DJ, Starr R, Mifsud S, Di Rago L. 1999. Aberrant hematopoiesis in mice with inactivation of the gene encoding SOCS-1. Leukemia 13:926-34
79. Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, Yamamura K. 1994. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver. Proc. Natl. Acad. Sci. USA 91:614-18
80. Young HA, Klinman DM, Reynolds DA, Grzegorzewski KJ, Nii A, Ward JM, Winkler-Pickett RT, Ortaldo JR, Kenny JJ, Komschlies KL. 1997. Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies. Blood 89:583-95
81. Alexander WS, Starr R, Fenner JF, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TWH, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98:597-608
82. Marine J-C, Topham DJ, McKay C, Wang D, Parganas E, Stravopodis D, Yoshimura A, Ihle JN. 1999. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell 98:609-16
83. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-20
84. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, Baca M, Alexander WS, Metcalf D, Hilton DJ, Nicola NA. 1999. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18;375-85
85. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A. 1999. Cytokine-inducible SH2 protein-3 (CIS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes to Cells 4:339-51
86. He W, Rose DW, Olefsky JM, Gustafson TA. 1998. Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J. Biol.Chem. 273:6860-67
87. Kasus-Jacobi A, Perdereau D, Auzan C, Clauser E, Van Obberghen E, Mauvais-Jarvis F, Girard J, Burnol A. 1998. Identification of the rat adapter Grb14 as an inhibitor of insulin actions. J. Biol. Chem. 273:26026-35
88. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, Nicola NA. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA 95:114-19
89. Matuoka K, Miki H, Takahashi K, Takenawa T. 1997. A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem. Biophys. Res. Commun. 239:488-92
90. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. 1998. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93:827-39
91. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. 1998. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell 4:619-25
92. Auernhammer CJ, Chesnokova V, Bousquet C, Melmed S. 1998. Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol. Endocrinol. 12:954-61
93. Helman D, Sandowski, Y, Cohen Y, Matsumoto A, Yoshimura A, Merchav S, Gertler A. 1998 Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling FEBS Lett. 441,287-91
94. Ito S, Ansari P, Sakatsume M, Dickensheets H, Vazquez N, Donnelly RP, Larner AC, Finbloom DS. 1999. Interleukin-10 inhibits expression of both interferon alpha-and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456-63
95. Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, Scapini P, Marchi M, Suzuki R, Suzuki A, Yoshimura A. 1999. EL-10 selectively enhances CIS3SOCS3 expression in human neutrophils. Evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood. 94:2880-89
96. Cohney SJ, Sanden D, Cacalano NA, Yoshimura A, Mui A, Migone TS, Johnston JA. 1999. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol. Cell. Biol. 19:4980-88
97. Auernhammer CJ, Bousquet C, Melmed S. 1999. Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc. Natl. Acad. Sci. USA 96:6964-69
98. Marine J-C, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimure A, Ihle JN. 1999. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98: 617-27
99. Dey BR, Spence SL, Nissley P, Furlanetto RW. 1998. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J. Biol. Chem. 273:24095-101
100. Stebbins CE, Kaelin WG Jr, Pavletich NP. 1999. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455-61
101. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG Jr, Elledge SJ, Conaway RC, Harper JW, Conaway JW. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284:657-61